MicroRNA fingerprints during human megakaryocytopoiesis
Described herein is a method of decreasing expression of HOXA1 in a subject having a cancer and/or myeloproliferative disorder associated with overexpression of a HOXA1 gene product where an effective amount of at least one miR-10a gene product or an isolated variant or biologically-active fragment thereof is administered to the subject sufficient to decrease expression of the HOXA1 gene product in the subject.
1. A method of decreasing expression of a transcription factor gene product from the homeobox gene family (HOXA1) in a subject having a cancer and/or myeloproliferative disorder associated with overexpression of a HOXA1 gene product, comprising
administering an effective amount of at least one miR-10a gene product or an isolated variant or biologically-active fragment thereof to the subject sufficient to decrease expression of the HOXA1 gene product in the subject, wherein the cancer and/or myeloproliferative disorder is selected from the group consisting of: acute myeloid leukemia (AML), acute megakaryoblastic leukemia (AMKL), multiple myeloma (MM), and chronic myelogenous leukemia (CML).
2. The method of claim 1 , wherein the at least one miR-10a gene product or isolated variant or biologically-active fragment thereof comprises a nucleotide sequence that is complementary to a nucleotide sequence in the HOXA1 gene product.
3. The method of claim 1 wherein the cancer and/or myeloproliferative disorder is acute myeloid leukemia.
4. The method of claim 3 , wherein the acute myeloid leukemia is acute megakaryoblastic leukemia.
5. The method of claim 1 , wherein the cancer and/or myeloproliferative disorder is multiple myeloma.
6. The method of claim 1 , wherein the cancer and/or myeloproliferative disorder is chronic myelogenous leukemia (CML).
7. The method of claim 1 , wherein the subject is a human.